What does this research mean for the field?

Continuous glucose monitoring (CGM) provides significant psychosocial and behavioral benefits for young adults with type 1 or type 2 diabetes, including enhanced confidence, safety, more informed therapy decisions, and reduced management burden. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 7, 2026

1556-P: Beyond Glucose: Understanding the Psychosocial and Behavioral Value of Dexcom CGM among Young Adults with Diabetes

Key Points

This study aims to evaluate the psychosocial and behavioral value of Dexcom CGM among young adults with diabetes.
Analyzed Dexcom device data and survey responses from users aged 18-25 years.
Summarized glycemic metrics and CGM use patterns over the prior 3 months.
Stratified analyses by diabetes type, age, gender, pump/AID use, and Dexcom Share use.
Participants included 405 with T1D and 102 with T2D, with median CGM use duration of 2.2 years for T1D and 0.6 years for T2D.
Overall CGM use was 91% for T1D vs 68% for T2D, with significant psychosocial benefits reported across groups.
Share users reported greater motivation for physical activity and enhanced support networks compared to non-Share and MDI users.

Abstract

Introduction and Objective: Young adulthood is a critical period for establishing diabetes self-management, yet limited evidence describes the psychosocial and behavioral value of CGM for this group. This real-world, observational study evaluated the perceived value, daily life impact, and patterns of Dexcom CGM use among young adults with T1D or T2D. Methods: Dexcom device data and survey responses were analyzed for users aged 18-25 years. Glycemic metrics, CGM use, and feature use were summarized for the prior 3 months. Analyses were stratified by diabetes type, age, gender, pump/AID use, and Dexcom Share use. Between-group differences were assessed. Results: Sample included 405 T1D (mean ± SD age 21± 2 years; diabetes duration 8 ± 6 years; 66% female); and 102 T2D (age 22 ± 2 years; diabetes duration 4 ± 4 years; 80% female) participants. Median IQR duration of Dexcom CGM use was 2.2 years 0.9, 3.7 for T1D vs T2D 0.6 0.3, 1.3; % CGM use was 91% 68, 96 for T1D vs T2D 68% 35, 92. TIR differed (T1D 64% 48, 74 vs T2D 81% 45, 95) but did not influence perceived value. Nearly all users identified reduced fingersticks as the most valued benefit. Share use was 20% among T1D (median followers 2 1,5) and 17% among T2D (2 1,3). Across groups, CGM supported more informed dosing or medication decisions, greater spontaneity, better recognition of food and stress effects, and stronger sense of control and safety. Among T1D, Share users reported greater motivation for physical activity vs non-Share users, and pump/AID users reported higher confidence and stronger support networks vs MDI users (all p0.05). Age- and gender-stratified analyses revealed differences in glycemic patterns, perceived value, and engagement behaviors. Conclusion: Young adults with T1D or T2D reported meaningful psychosocial, behavioral, and daily-life benefits from Dexcom CGM. Across groups, CGM strengthened confidence, enhanced safety, supported more informed therapy decisions, and reduced management burden. Disclosure M. Crawford: Employee; Current; Dexcom, Inc. C. Hicks: Employee; Current; Dexcom, Inc. T. Eren: Employee; Current; Dexcom, Inc. N. Gopisetty: Employee; Current; Dexcom, Inc. H. Singh: Employee; Current; Dexcom, Inc.

Demander à l'IA

Bookmark